Abstract: Background: HIV virological failure still remains a problem in HV/AIDS treatment and care. This study aimed to describe the prevalence and identify the factors associated with viral non-suppression among HIV-positive adult patients on antiretroviral therapy in Woliso Town, Oromia, Ethiopia. Methods: A retrospective cross-sectional study was conducted among 424 HIV-positive patient’s attending antiretroviral therapy (ART) in Woliso Town during the period from August 25, 2020 to August 30, 2020. Data collected from patient medical records were entered into Epi Info version 2.3.2.1 and exported to SPSS version 21.0 for analysis. Logistic regression analysis was done to identify factors associated with viral load non-suppression, and statistical significance of odds ratios were declared using 95% confidence interval and p-value < 0.05. Results: A total of 424 patients were included in this study. The mean age (± SD) of the study participants was 39.88 (± 9.995) years. The prevalence of HIV viral load non-suppression was 55 (13.0%) with 95% CI (9.9-16.5). Second-line ART treatment regimen (Adjusted Odds Ratio (AOR) = 8.98, 95% Confidence Interval (CI): 2.64, 30.58) and routine viral load testing (AOR = 0.01, 95% CI: 0.001, 0.02) were significantly associated with virological non-suppression. Conclusion: Virological non-suppression was high, which hinders the achievement of the third global 95 target. The second-line regimen and routine viral load testing were significantly associated with virological non-suppression. It suggests the need to assess the effectiveness of antiretroviral drugs for epidemic control. It also clearly shows the need to decentralize third-line ART treatment for those patients in need.
Abstract: The Aptima® HIV-1 Quant Dx Assay is a fully
automated assay on the Panther system. It is based on Transcription-
Mediated Amplification and real time detection technologies. This
assay is intended for monitoring HIV-1 viral load in plasma
specimens and for the detection of HIV-1 in plasma and serum
specimens.
Nine-hundred and seventy nine specimens selected at random
from routine testing at St Thomas’ Hospital, London were
anonymised and used to compare the performance of the Aptima
HIV-1 Quant Dx assay and Roche COBAS® AmpliPrep/COBAS®
TaqMan® HIV-1 Test, v2.0. Two-hundred and thirty four specimens
gave quantitative HIV-1 viral load results in both assays. The
quantitative results reported by the Aptima Assay were comparable to
those reported by the Roche COBAS AmpliPrep/COBAS TaqMan
HIV-1 Test, v2.0 with a linear regression slope of 1.04 and an
intercept on -0.097.
The Aptima assay detected HIV-1 in more samples than the
COBAS assay. This was not due to lack of specificity of the Aptima
assay because this assay gave 99.83% specificity on testing plasma
specimens from 600 HIV-1 negative individuals. To understand the
reason for this higher detection rate a side-by-side comparison of low
level panels made from the HIV-1 3rd international standard
(NIBSC10/152) and clinical samples of various subtypes were tested
in both assays. The Aptima assay was more sensitive than the
COBAS assay.
The good sensitivity, specificity and agreement with other
commercial assays make the HIV-1 Quant Dx Assay appropriate for
both viral load monitoring and detection of HIV-1 infections.